Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein
W O
WO
Virchow-Klinikum, Universitätsklinikum, Humboldt-Universität zu Berlin, Germany.
Neuhaus
P
P
McMaster
P
P
Calne
R
R
Pichlmayr
R
R
Otto
G
G
Williams
R
R
Ericzon
B G
BG
Bismuth
H
H
D000206:Actuarial Analysis; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus